Latest News & Features
Americas
US-based injections maker Akorn has agreed to sell its rights to develop, manufacture and market generic tuberculosis injection rifampin to Watson Laboratories to settle charges by the US Federal Trade Commission (FTC) that its proposed acquisition of pharmaceutical company VersaPharm was likely to be anticompetitive. 5 August 2014
Americas
Anglo-Swedish pharmaceutical company AstraZeneca has sued India-based Zydus for infringing three patents related to its heartburn drug Nexium (esomeprazole magnesium). 4 August 2014
Generics
HemoShear creates systems for predicting human responses to drugs by applying its proprietary technology
to human cells in the lab to make them behave the way they would in vivo. LSIPR found out about its strategy for protecting and developing its technologies. 1 August 2014
Big Pharma
Parties need to take care when considering interim injunctions and keep an eye on future IP litigation, says Jan Lindberg. 1 August 2014
article
The development of gene technologies is still at a relatively early stage, with patent applications coming from research institutes and universities as well as industry. Gareth Williams has crunched the numbers. 1 August 2014
Americas
German pharmaceutical company Boehringer Ingelheim has sued generic drug maker Mylan for infringing a patent covering its Aggrenox drug. 31 July 2014
Americas
Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million. 31 July 2014
Americas
The expiration of US pharmaceutical company Pfizer’s patent for Viagra in many European countries was a contributing factor to the drop in revenue that it reported yesterday (July 29) when releasing its second-quarter earnings data. 30 July 2014
Big Pharma
UK-based pharmaceutical company AstraZeneca has boosted its patent portfolio with the acquisition of rights to Spanish company Almirall’s lung drugs, including Eklira (aclidinium). 30 July 2014
Americas
US officials have accepted an application by Novartis to market a biosimilar of Amgen’s Neupogen (filgrastim) drug, a move thought to be the first of its kind. 29 July 2014